Patents by Inventor Alissa Chackerian

Alissa Chackerian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CANCER COMBINATION THERAPIES COMPRISING CTLA-4 AND PD-1 BLOCKING AGENTS
    Publication number: 20220411507
    Abstract: Anti-cancer combination therapies comprising a CTLA-4 blocking agent and a PD-1 blocking agent are disclosed. In particular, combination therapies are disclosed wherein the CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment and the PD-1 blocking agent is an anti-PD-1 or anti-PD-L1 antibody, or antibody fragment thereof.
    Type: Application
    Filed: March 10, 2020
    Publication date: December 29, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Drake LaFace, Juha Punnonen, Edward Bowman, David Bauche, Alissa Chackerian, Jeffery Grein, Smita Mauze, Anandi Sawant, Lakshmanan Annamalai
  • METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
    Publication number: 20220206012
    Abstract: Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.
    Type: Application
    Filed: August 3, 2021
    Publication date: June 30, 2022
    Inventor: Alissa A. Chackerian
  • Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels
    Patent number: 11079393
    Abstract: Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: August 3, 2021
    Assignee: BIOGEN MA INC.
    Inventor: Alissa A. Chackerian
  • METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
    Publication number: 20160291035
    Abstract: Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.
    Type: Application
    Filed: April 18, 2016
    Publication date: October 6, 2016
    Inventor: Alissa A. Chackerian
  • USE OF IL-23 ANTAGONISTS FOR TREATMENT OF INFECTION
    Publication number: 20140147442
    Abstract: Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.
    Type: Application
    Filed: October 28, 2013
    Publication date: May 29, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Manfred Kopf, Luigina Romani, Robert A. Kastelein, Alissa A. Chackerian
  • METHODS FOR MODULATING IL-33 ACTIVITY
    Publication number: 20140105887
    Abstract: Provided herein are methods of modulating IL-33 activity, e.g., for the purpose of treating immune diseases and conditions, as well as methods of screening for compounds capable antagonizing IL-33 signaling.
    Type: Application
    Filed: August 9, 2013
    Publication date: April 17, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Alissa A. Chackerian, Robert A. Kastelein
  • METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS
    Publication number: 20130337470
    Abstract: Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAd-CAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.
    Type: Application
    Filed: October 24, 2011
    Publication date: December 19, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventor: Alissa A. Chackerian
  • Use of IL-23 antagonists for treatment of infection
    Patent number: 8586035
    Abstract: Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: November 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Manfred Kopf, Luigina Romani, Robert A. Kastelein, Alissa A. Chackerian
  • METHODS FOR MODULATING IL-33 ACTIVITY
    Publication number: 20120207752
    Abstract: Provided herein are methods of modulating IL-33 activity, e.g., for the purpose of treating immune diseases and conditions, as well as methods of screening for compounds capable antagonizing IL-33 signaling.
    Type: Application
    Filed: April 25, 2012
    Publication date: August 16, 2012
    Applicant: Schering Corporation
    Inventors: Alissa A. Chackerian, Robert A. Kastelein
  • Method of treating asthma or allergy by administering an IL-33 receptor antibody
    Patent number: 8187596
    Abstract: Provided herein are methods of modulating IL-33 activity, e.g., for the purpose of treating immune diseases and conditions, as well as methods of screening for compounds capable antagonizing IL-33 signaling.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: May 29, 2012
    Assignee: Schering Corporation
    Inventors: Alissa A. Chackerian, Robert A. Kastelein
  • SELECTIVE INTEGRIN INHIBITORS
    Publication number: 20120059029
    Abstract: This invention provides methods for selectively antagonizing the ?4?1 integrin heterodimer in a subject in need thereof, and preferably in a human subject. The methods of the invention utilize conjugates comprising two or more ?4?1 small molecule antagonists covalently attached to a biocompatible polymer. These methods of selectively inhibiting ?4?1 may be used modulate both normal and pathological biological processes mediated at least in part through ?4?1 activity.
    Type: Application
    Filed: May 2, 2011
    Publication date: March 8, 2012
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Anthony Pepio, Gordon Francis, Theodore A. Yednock, Alissa Chackerian, Brian Todd Wipke
  • USE OF IL-23 ANTAGONISTS FOR TREATMENT OF INFECTION
    Publication number: 20100291084
    Abstract: Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.
    Type: Application
    Filed: February 8, 2008
    Publication date: November 18, 2010
    Inventors: Manfred Kopf, Luigina Romani, Robert A. Kastelein, Alissa A. Chackerian
  • IL-33 receptor
    Patent number: 7560530
    Abstract: Provided herein are methods of modulating IL-33 activity, e.g., for the purpose of treating immune diseases and conditions, as well as methods of screening for compounds capable antagonizing IL-33 signaling.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: July 14, 2009
    Assignee: Schering Corporation
    Inventors: Alissa A. Chackerian, Robert A. Kastelein